Literature DB >> 2914447

Aminoglycoside pharmacokinetics: dosage requirements and nephrotoxicity in trauma patients.

P L Townsend1, M P Fink, K L Stein, S G Murphy.   

Abstract

We evaluated prospectively gentamicin and tobramycin pharmacokinetics in 37 patients with multiple system trauma and seven patients with isolated closed head trauma. The mean apparent volume of distribution (Vd) was 0.38 +/- 0.10 and 0.27 +/- 0.04 L/kg actual body weight (ABW) in patients with multiple trauma and closed head trauma, respectively. The difference in Vd between the two groups of patients was significant (p less than .002). Vd was not predictable on the basis of age, sex, weight, trauma score, or hospital day that therapy was initiated. Mean aminoglycoside clearance (Cl) was 123 +/- 46 ml/min. Neither serum creatinine nor estimated creatinine Cl predicted aminoglycoside Cl with sufficient accuracy to be clinically useful (r = .33 and .67, respectively). The mean daily dose was 6.1 +/- 1.6 mg/kg. The mean peak serum level was 5.8 +/- 1.3 micrograms/ml. Only one patient developed clinically significant renal dysfunction. Our data indicate that a loading dose of gentamicin or tobramycin of 3 mg/kg ABW in patients with multiple trauma and 2.5 mg/kg ABW in patients with isolated head trauma will obtain a mean initial peak serum level of 6.6 micrograms/ml. Although adequate maintenance dosing requires individualization based on pharmacokinetic analyses, large aminoglycoside doses can be used safely in patients with blunt trauma if appropriate monitoring is employed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2914447

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  8 in total

1.  Bayesian forecasting of serum gentamicin concentrations in intensive care patients.

Authors:  K A Rodvold; R D Pryka; P G Kuehl; R A Blum; P Donahue
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

Review 2.  Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability.

Authors:  Federico Pea; Pierluigi Viale; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 3.  Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.

Authors:  Jason A Roberts; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants, and children.

Authors:  J M Tréluyer; Y Merlé; S Tonnelier; E Rey; G Pons
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

5.  Pharmacokinetics of antibiotics in critically ill patients.

Authors:  R van Dalen; T B Vree
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

6.  Population pharmacokinetics of ceftazidime in intensive care unit patients: influence of glomerular filtration rate, mechanical ventilation, and reason for admission.

Authors:  Bernard Georges; Jean-Marie Conil; Thierry Seguin; Stéphanie Ruiz; Vincent Minville; Pierre Cougot; Jean-François Decun; Hélène Gonzalez; Georges Houin; Olivier Fourcade; Sylvie Saivin
Journal:  Antimicrob Agents Chemother       Date:  2009-07-27       Impact factor: 5.191

Review 7.  Aminoglycosides--50 years on.

Authors:  E J Begg; M L Barclay
Journal:  Br J Clin Pharmacol       Date:  1995-06       Impact factor: 4.335

8.  Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy.

Authors:  Arantxazu Isla; Alicia Rodríguez-Gascón; Iñaki F Trocóniz; Lorea Bueno; María Angeles Solinís; Javier Maynar; José Angel Sánchez-Izquierdo; José Luis Pedraz
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.